A Phase III, Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Investigate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of RO7200220 Administered Intravitreally in Patients with Uveitic Macular Edema (Sandcat)
research
CapriCORN
Comprehensive Analysis of Pathogens, Resistomes, and Inflammatory-markers in the Cornea
RECORDATI MT8
Efficacy, Safety and Pharmacokinetics of 3 Doses of REC 0/0559 Eye Drops (MT8) for the Treatment of Stage 2 (Moderate) and 3 (Severe) Neurotrophic Keratitis in Adult Patients
IMVT TED
A Phase 3, Multi-center, Randomized, Quadruple-masked, Placebo-controlled Study of Batoclimab for the Treatment of Participants with Active Thyroid Eye Disease (TED)
Lab-Grown Retinal Eye Cells Open Door For Clinical Trials to Treat Blindness
Retinal cells grown from stem cells can reach out and connect with neighbors, according to a new study, completing a “handshake” that may show the cells are ready for trials in humans with degenerative eye disorders.
UW Researcher Receives Grant to Expand Knowledge of Molecules Regulating Retinal Function
Mrinalini Hoon, PhD, has been granted a $150,000 Research to Prevent Blindness (RPB) Career Advancement Award.
New Research May Shed Light on Impact of Toxic Metals on Aging Dogs
New research led by a University of Wisconsin–Madison assistant professor could shed some light on whether toxic metals commonly found in and around the home could impact an older dog’s vision and overall health.
UW-Madison Launches New Ophthalmology Tissue Biobank
The University of Wisconsin Department of Ophthalmology and Visual Sciences (DOVS) has entered into a new partnership aimed at systematically collecting, storing, processing and distributing human eye tissue for research purposes.
IZOKIBEP (IL-17A)
To assess the safety, tolerability, and immunogenicity of izokibep in subjects with active non-infectious, intermediate-, posterior- or pan-uveitis requiring high-dose steroids.
GALE
To assess the long-term efficacy and safety of multiple intravitreal injections of APL-2 in subjects with geographic atrophy secondary to age-related macular degeneration.